rbsmorgans:biota " buy", page-8

Some of the figures in the detail are interesting:

Forecasting Sales:

.........$M
2011:...16.4
2012:...54.1
2013:...54.6

From Chart 1, the 2012 & 2013 sales represent royalties of about $25M and $20M from Relenza and Inavir.

EBITDA:

.........$M
2011:...(17.9)
2012:... 17.6
2013:... 37.1

Cash & deposits balance 30 June

..........$M
2011:... 88.5
2012:... 97.1
2013:...123.0

They indicate that the key issue is an upcoming decision on non-dilutive funding in relation to funding of the LANI trial.

Regards

SP